Drug Development.

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) is a primary cause of dementia, impacting global health and demanding new treatments.
• Natural compounds offer potential therapeutic avenues with fewer side effects compared to traditional treatments.
• Investigating combined natural alkaloid and Insulin-like Growth Factor 1 (IGF-1) effects on amyloid-beta (Aβ)-induced neurotoxicity.

Purpose of the Study:

• To assess the neuroprotective potential of a natural alkaloid and IGF-1 against Aβ-induced neurotoxicity in a cellular model.
• To evaluate the combined impact of these agents on key Alzheimer's disease pathological markers.
• To explore a novel therapeutic strategy for Alzheimer's disease.

Main Methods:

• SH-SY5Y cells were cultured and exposed to amyloid-beta (Aβ) to induce neurotoxicity.
• Determined optimal doses for the natural alkaloid and IGF-1 via IC50 and dose-response studies.
• Assessed cell viability (MTT), oxidative stress (ROS, MDA, GSH, SOD, catalase), apoptosis, neuronal health (NeuN, cresyl violet), and molecular pathways (GSK-3β, β-catenin).

Main Results:

• Combined treatment significantly enhanced cell viability in Aβ-exposed cells.
• Reduced reactive oxygen species (ROS) and apoptosis, mitigating oxidative stress and cell death.
• Improved neuronal markers and modulated GSK-3β and β-catenin activities, suggesting therapeutic potential.

Conclusions:

• The combination of a natural alkaloid and IGF-1 demonstrates significant neuroprotective effects against Aβ toxicity.
• This synergistic approach presents a promising novel therapeutic strategy for Alzheimer's disease.
• Further research is needed to elucidate detailed mechanisms and validate efficacy in in vivo models.